Searching for the right chemistry
Article Abstract:
A planned merger between SmithKline Beecham and Glaxo Wellcome will bring benefits in terms of research and development, as well as cost savings. The new company would be able to carry out major drug development projects, and some 1 billion pounds sterling of cost savings could be achieved. Vanguard Medica, a biotechnology company developing a drug to combat migraine with SmithKline Beecham, saw a drop in its stock price after the agreement was announced. Glaxo is a leader in the world migraine treatment market.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Patent row kills merger
Article Abstract:
A planned merger between SmithKline Beecham and Glaxo Wellcome has collapsed. Questions have arisen over the patent position of Paxil, an antidepressant, and Augmentin, an antibiotic, both from SmithKline Beecham. The company says the the patents expire in 2006 and 2001 respectively, but generic producers disagree. SmithKline Beecham blames Glaxo for the collapse of the planned merger. There were disagreements over who would rank third in the new company, and there may have been disagreements over the equity split.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Searching for the grail. Going for e-broke
- Abstracts: Growing into the distance. Zeroing in. Balancing the books
- Abstracts: Employee motivation: the new corporate family. Net gains
- Abstracts: So farewell then, BES. Real growth stocks. High stakes
- Abstracts: Big banks hit at competitors. Online banks off target. Banks